ReShape Lifesciences Inc.
RSLS
$2.90
$0.6126.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -38.34% | -21.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -38.34% | -21.25% | |||
| Cost of Revenue | -11.11% | -43.02% | |||
| Gross Profit | -48.37% | -8.34% | |||
| SG&A Expenses | 49.72% | -48.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.64% | -39.62% | |||
| Operating Income | -186.45% | 63.54% | |||
| Income Before Tax | 184.34% | -11.49% | |||
| Income Tax Expenses | 40.00% | -16.67% | |||
| Earnings from Continuing Operations | 183.70% | -11.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 183.70% | -11.39% | |||
| EBIT | -186.45% | 63.54% | |||
| EBITDA | -188.07% | 63.72% | |||
| EPS Basic | 130.75% | 20.55% | |||
| Normalized Basic EPS | 131.12% | 22.11% | |||
| EPS Diluted | 130.75% | 20.55% | |||
| Normalized Diluted EPS | 131.12% | 22.11% | |||
| Average Basic Shares Outstanding | 172.63% | 39.71% | |||
| Average Diluted Shares Outstanding | 172.63% | 39.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||